CD14 and hereditary angioedema: A similar observation was made when comparing CD14++CD16− in the group of healthy subjects and HAE patients in remission (86.3%; 32.4–95.6% vs. 75.4%; 17.9–93.4%, p = 0.01, Figure 2/Table 1).